Dr Reddys Laboratories (RDY) Income towards Parent Company (2009 - 2023)
Dr Reddys Laboratories (RDY) posted quarterly Income towards Parent Company of $178.0 million for Q2 2023, up 5.33% quarter-over-quarter from $169.0 million in Q1 2023.
Dr Reddys Laboratories (RDY) Income towards Parent Company (2009 - 2023) Analysis & Trends
Dr Reddys Laboratories' Income towards Parent Company history runs 15 years deep, the most recent figure standing at $178.0 million for Q2 2023.
- In Q2 2023, Income towards Parent Company changed N/A year-over-year to $178.0 million; the TTM figure through Mar 2026 stood at $178.0 million (down 48.7% YoY), while the FY2026 annual figure was $456.0 million, down 31.22% from the prior year.
- Income towards Parent Company for Q2 2023 stood at $178.0 million, up from $169.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $178.0 million in Q2 2023, with the low at -$108.0 million in Q3 2020.
- The 5-year median for Income towards Parent Company is $105.5 million (2019), against an average of $80.2 million.
- Peak annual rise in Income towards Parent Company reached 121.74% in 2019, while the deepest fall reached 214.29% in 2019.
- Dr Reddys Laboratories' Income towards Parent Company stood at -$80.0 million in 2019, then plunged by 35.0% to -$108.0 million in 2020, then surged by 224.07% to $134.0 million in 2021, then slipped by 12.69% to $117.0 million in 2022, then soared by 52.14% to $178.0 million in 2023.
- Business Quant data shows RDY's Income towards Parent Company at $178.0 million in Q2 2023, $169.0 million in Q1 2023, and $117.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 178.00 Mn |
| Mar 31, 2023 | 169.00 Mn |
| Dec 31, 2022 | 117.00 Mn |
| Sep 30, 2022 | 152.00 |
| Jun 30, 2021 | 134.00 Mn |
| Mar 31, 2021 | 77.00 Mn |
| Sep 30, 2020 | -108.00 Mn |
| Jun 30, 2020 | 149.00 Mn |
| Mar 31, 2020 | 79.00 Mn |
| Sep 30, 2019 | -80.00 Mn |
| Jun 30, 2019 | 153.00 Mn |
| Mar 31, 2019 | 94.00 Mn |
| Dec 31, 2018 | 63.00 Mn |
| Sep 30, 2018 | 70.00 Mn |
| Jun 30, 2018 | 69.00 Mn |
| Mar 31, 2018 | 63.00 Mn |
| Dec 31, 2017 | 44.00 Mn |
| Sep 30, 2017 | 51.00 Mn |
| Dec 31, 2016 | 48.00 Mn |
| Sep 30, 2016 | 85.00 Mn |